Big Pharma USA Meanwhile, there are increasing reports that the DEA will follow the recommendation to include cannabis in Schedule 3. If this happens, pharmacies in the US will be allowed to sell cannabis as a pharmaceutical product. Things really seem to be moving in the US - it may not be legalization, but it's a clear benefit to pharmaceutical companies. Now it's getting really exciting - this is a huge market that lies at the feet of Medipharm Labs and its global pharma partner.